Timber Pharmaceuticals Inc (TMBR) USD0.001
Timber Pharmaceuticals, Inc. (Timber) is a clinical-stage biopharmaceutical company. It is focused on development of treatments for orphan dermatologic diseases. It Is also focused on developing non-systemic treatments for dermatologic diseases, including congenital ichthyosis, facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma. The Company's pipeline programs include TMB-001, TMB-002 and TMB-003. TMB-001 is topical formulation of isotretinoin, evaluated in a Phase II b clinical trial for the treatment of congenital ichthyosis (CI), a genetic keratinization. TMB-002 is a topical formulation of rapamycin, evaluated in a Phase II b clinical trial for the treatment of FAs in TSC, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. TMB-003 is a formulation of sitaxsentan in the preclinical development for the treatment of scleroderma, a rare connective tissue disorder characterized by abnormal thickening of the skin.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.